{"id":48157,"date":"2024-11-14T12:40:05","date_gmt":"2024-11-14T11:40:05","guid":{"rendered":"https:\/\/www.bricbordeaux.com\/event\/invited-seminar-jean-philippe-girard\/"},"modified":"2024-11-21T15:44:17","modified_gmt":"2024-11-21T14:44:17","slug":"invited-seminar-jean-philippe-girard","status":"publish","type":"tribe_events","link":"https:\/\/www.bricbordeaux.com\/en\/event\/invited-seminar-jean-philippe-girard\/","title":{"rendered":"BRIC prestige seminar: Jean-Philippe Girard"},"content":{"rendered":"

Jean-Philippe Girard<\/strong><\/a>, Directeur de Recherche INSERM<\/p>\n

CNRS Silver Medal Biologie Vasculaire: Cellules endoth\u00e9liales dans l\u2019Immunit\u00e9, l\u2019Inflammation et le Cancer<\/a>”
\nIPBS<\/a>-CNRS (Institut de pharmacologie et de biologie structurale), Universit\u00e9 de Toulouse, Toulouse, France.<\/p>\n

High endothelial venules (HEVs) : specialized blood vessels for lymphocyte entry in tumors during cancer immunotherapy<\/strong><\/p>\n

Conference in English.
—<\/strong><\/p>\n

Tuesday, December 10, 2024, 2:30 p.m.<\/p>\n

conference room BBS (Bordeaux, Biologie Sant\u00e9) 2 rue Dr Hoffmann Martinot – Site Carreire Universit\u00e9 de Bordeaux<\/p>\n

 <\/p>\n

Keywords<\/strong><\/p>\n

Tumor microenvironnement, Tumor-infiltrating lymphocytes, Cancer immunotherapy<\/p>\n

 <\/p>\n

Abstract<\/strong><\/p>\n

Immunotherapy, a therapeutic strategy aimed at increasing the activity of the immune system, has revolutionized cancer treatment over the past decade. A better understanding of how this therapeutic approach works, and more particularly how killer lymphocytes access tumors during immunotherapy, could improve the efficacy of the treatments. We recently discovered the essential role played in this process by specialized blood vessels known as tumor-associated high endothelial venules (TA-HEVs) (Asrir* et al. Cancer Cell 2022). TA-HEVs share important phenotypic and functional characteristics with HEVs in lymph nodes and other lymphoid organs (Moussion and Girard, Nature 2011 ; Girard et al, Nature Rev Immunol 2012). For the first time, we were able to film the lymphocytes infiltrating TA-HEV walls to enter the tumors. We found that increasing the proportion of TA-HEVs in a tumor improves the infiltration of stem-like CD8+ T cells, the efficacy of the immunotherapy and leads to the eradication of the tumors. Finally, we showed that the likelihood of recovery of metastatic melanoma patients treated with anti-PD-1 plus anti-CTLA-4 immunotherapy is increased when a large number of TA-HEVs are present in tumors. Together our results suggest that increasing the density of TA-HEVs in human tumors could increase lymphocyte infiltration, making immunotherapy effective in a greater number of patients. <\/p>\n

<\/strong><\/p>\n

References<\/strong><\/p>\n

Asrir, A.*, Tardiveau; C.*, Coudert, J.*, Laffont, R.*, Blanchard, L.*, Bellard, E., Veerman, K., Bettini, S., Lafouresse, F., Vina, E., Tarroux, D., Roy, S., Girault, I., Molinaro, I., Martins, F., Scoazec, J.Y., Ortega, N., Robert, C. and Girard, J.P<\/u>. (2022) Tumor-associated HEVs mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy. Cancer Cell<\/strong>, 40:318-334 (article s\u00e9lectionn\u00e9 dans \u2018Best of Cancer Cell 2022<\/strong>\u2019, \u2018Highly cited article\u2019 du Web of Science; 157 citations dans Google Scholar).<\/p>\n

Girard, J.P<\/u>., Moussion, C., and Forster, R. (2012). HEVs, lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol<\/strong> 12<\/em>, 762-773.<\/p>\n

Moussion, C., and Girard, J.P<\/u>. (2011). Dendritic cells control lymphocyte entry to lymph nodes through high endothelial venules. Nature<\/strong> 479<\/em>, 542-546.<\/p>\n

 <\/p>\n

Biosketch<\/strong><\/p>\n

Jean-Philippe Girard (PhD) currently holds a position of Senior Research Director at INSERM (French NIH) at IPBS-CNRS, a large Research Center from the CNRS and the University of Toulouse (France). He received his Ph.D. in Molecular Biology from the University of Toulouse and did his postdoctoral training in Immunology and Vascular Biology at Harvard Medical School (USA) with Pr Tim Springer. Jean-Philippe Girard\u2019s research focuses on the role of high endothelial venules (HEVs) and interleukin-33 (IL-33) in immunity, inflammation and cancer. He discovered the alarmin cytokine IL-33 as a nuclear factor of HEV (NF-HEV). HEV blood vessels are portals of entry for lymphocytes into lymphoid organs (Moussion and Girard, Nature 2011; Girard et al, Nature Rev Immunol 2012). He showed that blood vessels with HEV characteristics designated tumor-associated HEVs are the main sites of lymphocyte entry into tumors, and are associated with response to immune checkpoint blockade (Asrir* et al Cancer Cell 2022). Dr. Girard is a Highly Cited Researcher in Immunology according to the Web of Science (HCR Index 2023). He received several Scientific Prizes for his work, including the CNRS Silver Medal (2103), and Prizes from the National Academy of Sciences (2012), the National Academy of Medecine (2013), \u2018Fondation pour la Recherche M\u00e9dicale\u2019 (2016), \u2018Fondation de France\u2019 (2018) and \u2018Fondation ARC\u2019 (2024). <\/p>\n

Jean-Philippe Girard<\/a> is invited by Team 9 Sarcotarget to sit on the jury for Florent Peyraud’s thesis defense on the same day.
\n<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Jean-Philippe Girard, Directeur de Recherche INSERM CNRS Silver Medal 2013, Team leader “Biologie Vasculaire: Cellules endoth\u00e9liales dans l\u2019Immunit\u00e9, l\u2019Inflammation et le Cancer” IPBS-CNRS (Institut de pharmacologie et de biologie structurale), Universit\u00e9 de Toulouse, Toulouse, France. High endothelial venules (HEVs) : specialized blood vessels for lymphocyte…<\/p>\n","protected":false},"author":3,"featured_media":48191,"template":"","meta":{"_tribe_events_status":"","_tribe_events_status_reason":"","footnotes":""},"tags":[],"tribe_events_cat":[91,93],"class_list":["post-48157","tribe_events","type-tribe_events","status-publish","has-post-thumbnail","hentry","tribe_events_cat-meetings-en","tribe_events_cat-seminars-en","cat_meetings-en","cat_seminars-en"],"_links":{"self":[{"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/tribe_events\/48157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/tribe_events"}],"about":[{"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/types\/tribe_events"}],"author":[{"embeddable":true,"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/users\/3"}],"version-history":[{"count":3,"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/tribe_events\/48157\/revisions"}],"predecessor-version":[{"id":48193,"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/tribe_events\/48157\/revisions\/48193"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/media\/48191"}],"wp:attachment":[{"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/media?parent=48157"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/tags?post=48157"},{"taxonomy":"tribe_events_cat","embeddable":true,"href":"https:\/\/www.bricbordeaux.com\/en\/wp-json\/wp\/v2\/tribe_events_cat?post=48157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}